CD8A and neoplasm: Therefore, we can imagine that in NSCLC patients, individuals with C1/C2 genotype may have wider repertoire of antigenic peptides, including tumor antigens, presented to their HLA-C-restricted CD8+ cytotoxic T cells which can eradicate tumor cells.